REMAP-CAP Trial

All Done!

A bit more to do?    Log in


Why we’ve added Multi-Factor Authentication (MFA) to clinical projects. We’re acutely aware that some environments introduce real limitations around MFA — especially intensive care units (ICUs), where mobile phones are often prohibited due to hygiene protocols, electromagnetic interference concerns, or institutional policies. .

Access this article in our blog »




 

REMAP-CAP

REMAP-CAP is a Randomized, Embedded, Multifactorial Adaptive Platform trial for hospitalised patients with respiratory tract infections, including COVID-19. The aim of this global trial is to efficiently evaluate a range of interventions to improve outcomes for patients.

About the software

This is Spinnaker, a user friendly, bespoke application that helps researchers find answers to important medical questions. The team behind the platform can adapt the software to match your study and we are especially interested in doing this for novel trials.

Spinnaker is a cloud based, integrated software/database solution for randomising patients using any design methodology including response adaptive methods; backed up by an electronic data capture application that is intuitive and particular. The application also includes management functions to alert relevant people about events (e.g. SAE), to manage drug inventory and to report on progress.

You can read more on the Spinnaker website or contact Audrey on [email protected]

You can get to know us a little better through our blog and social media pages accessed via the logout screen of this trial.

Made with love in New Zealand.